| Literature DB >> 36061831 |
Maria Evsevieva1, Oksana Sergeeva1, Alena Mazurakova2, Lenka Koklesova2, Irina Prokhorenko-Kolomoytseva1, Evgenij Shchetinin1, Colin Birkenbihl3, Vincenzo Costigliola4, Peter Kubatka5, Olga Golubnitschaja6.
Abstract
Abstract: Cardiovascular disease remains the leading cause of disease burden globally with far-reaching consequences including enormous socio-economic burden to healthcare and society at large. Cardiovascular health is decisive for reproductive function, healthy pregnancy and postpartum. During pregnancy, maternal cardiovascular system is exposed to highly increased haemodynamic stress that significantly impacts health status of the mother and offspring. Resulting from sub-optimal maternal health conditions overlooked in pre-pregnancy time, progressive abnormalities can be expected during pregnancy and postpartum. Contextually, there are two main concepts to follow in the framework of predictive, preventive and personalised medicine, namely to develop:1. advanced screening of sub-optimal health conditions in young populations to predict and prevent individual health risks prior to planned pregnancies2. in-depth companion diagnostics during pregnancy to predict and prevent long-lasting postpartum health risks of the mother and offspring.Data collected in the current study demonstrate group-specific complications to health of the mother and offspring and clinical relevance of the related phenotyping in pre-pregnant mothers. Diagnostic approach proposed in this study revealed its great clinical utility demonstrating important synergies between cardiovascular maladaptation and connective tissue dysfunction. Co-diagnosed pre-pregnancy low BMI of the mother, connective tissue dysfunction, increased stiffness of peripheral vessels and decreased blood pressure are considered a highly specific maternal phenotype useful for innovative screening programmes in young populations to predict and prevent severe risks to health of the mother and offspring. This crucial discovery brings together systemic effects characteristic, for example, for individuals with Flammer syndrome predisposed to the phenotype-specific primary vascular dysregulation, pregnancy-associated risks, normal tension glaucoma, ischemic stroke at young age, impaired wound healing and associated disorders. Proposed maternal phenotyping is crucial to predict and effectively protect both the mother and offspring against health-to-disease transition. Pre-pregnancy check-up focused on sub-optimal health and utilising here described phenotypes is pivotal for advanced health policy. Plain English abstract: Cardiovascular health is decisive for reproductive function and healthy pregnancy. During pregnancy, maternal cardiovascular system may demonstrate health-to-disease transition relevant for the affected mother and offspring. Overlooked in pre-pregnancy time, progressive abnormalities can be expected during pregnancy and lifelong. Here we co-diagnosed maternal pre-pregnancy low bodyweight with systemic effects which may increase risks of pregnancy, eye and heart disorders and ischemic stroke at young age, amongst others. Innovative screening programmes focused on sub-optimal health in young populations to predict and to mitigate individual health risks prior to pregnancy is an essential innovation for health policy proposed.Entities:
Keywords: Antenatal foetal death; Anthropometry; Blood pressure; Body mass index; Bodyweight; Cardiovascular stress; Connective tissue dysfunction; Flammer syndrome phenotype; Foetal growth restriction; Gestational arterial hypertension; Gestational diabetes; Health policy; Health-to-disease transition; Hypotrophy; Individualised protection; Ischemic stroke; Maladaptation; Mitral valve prolapse; Mother; Offspring; Oligohydramnios; Phytochemicals; Population screening; Pre-pregnancy check-up; Predictive preventive personalised medicine (PPPM / 3PM); Preeclampsia; Pregnancy; Preterm birth; Primary care; Risk assessment; Sub-optimal health; Systemic effects; Vascular stiffness; Wound healing; Young populations
Year: 2022 PMID: 36061831 PMCID: PMC9437153 DOI: 10.1007/s13167-022-00294-1
Source DB: PubMed Journal: EPMA J ISSN: 1878-5077 Impact factor: 8.836
Fig. 1Scoring of the symptoms and signs specific for the connective tissue dysfunction in pregnant women stratified by corresponding pre-pregnancy body mass index (BMI); significance is demonstrated (P value)
Fig. 2Scoring of the symptoms and signs specific for the connective tissue dysfunction in pregnant women with (FS +) and without (FS −) Flammer syndrome phenotype; significance is demonstrated (P value)
Individual parameters measured to characterise haemodynamic and vascular status of pregnant women stratified by corresponding pre-pregnancy BMI; statistically significant P values are presented in bold letters and marked with an asterisk; statistically differences were demonstrated between the group 1 (low BMI) and group 3 (high BMI) specifically for parameters PSBP (113,9 ± 1,6 against 125,9 ± 1,27 mm Hg) and CSBP (101,7 ± 1,4 against 111,1 ± 1,16 mm Hg), as well as between group 2 (normal BMI) and group 3 (high BMI) specifically for parameters PSBP (116,1 ± 0,7 against 125,9 ± 1,27 mm Hg), RWVa (9,4 ± 0,1 against 10,1 ± 0,19 m/s), CSBP (103,6 ± 0,68 against 111,1 ± 1,16 mm Hg) and AIXa (3,08 ± 0,46 against 4,28 ± 0,41)
| Individual | BMI < 19 kg/m2 | BMI ranged | BMI > 25 kg/m2 | Significance |
|---|---|---|---|---|
Peripheral systolic blood pressure (PSBP), mm Hg | 113,9 ± 1,6 | 116,1 ± 0,7 | 125,9 ± 1,27 | |
Peripheral diastolic blood pressure (PDBP), mm Hg | 72,3 ± 1,5 | 72,8 ± 0,5 | 75,8 ± 1,1 | |
| Peripheral arterial vascular stiffness (brachial augmentation index, AIXb), % | − 32,5 ± 1,51 | − 49,7 ± 1,0 | − 44,4 ± 1,53 | |
Aortic reverse pulse wave velocity (RWVa), m/s | 9,7 ± 0,26 | 9,4 ± 0,1 | 10,1 ± 0,19 | |
Central systolic blood pressure (CSBP), mm Hg | 101,7 ± 1,4 | 103,6 ± 0,68 | 111,1 ± 1,16 | |
Central diastolic blood pressure (CDBP), mm Hg | 74,3 ± 1,5 | 74,9 ± 0,5 | 77,9 ± 1,05 | |
| Aortic vascular stiffness (aortic augmentation index, AIXa) % | 3,32 ± 0,54 | 3,08 ± 0,46 | 4,28 ± 0,41 |
Anthropometric parameters of newborns in groups of comparison stratified by corresponding BMI of their pre-pregnant mothers; statistically significant P values are presented in bold letters and marked with an asterisk; statistically significant differences were observed, in particular, for absolute majority of hypotrophic newborns (about 78%) in the group 1 (low BMI of pre-pregnant mothers) associated with low BMI < 12 kg/m2 in about 89% of all newborns in this group of comparison
| Anthropometric | BMI < 19 kg/m2 | BMI ranged | BMI > 25 kg/m2 | Significance |
|---|---|---|---|---|
| Hypotrophy | 77,8 (21) | 25,2 (52) | 13,7 (14) | |
| Normotrophy | 11,1 (3) | 54,2 (118) | 68,0 (62) | |
| Hypertrophy | 11,1 (3) | 25,0 (46) | 25,5 (26) | |
| BMI < 12 kg/m2 | 88,9 (24) | 33,3 (72) | 15,7 (16) | |
| BMI ≥ 12 kg/m2 | 11,1 (3) | 66,7 (144) | 84,3 (86) |
Pregnancy complications and weight gain particularities observed in 3 groups of comparison stratified by corresponding BMI of pre-pregnant mothers; antenatal foetal death was observed solely in group 1 (low BMI), whereas preterm birth was observed only in group 3 (high BMI); preeclampsia, gestational arterial hypertension and gestational diabetes were more frequent in group 3, in contrast to foetal growth restriction monitored in group 1 only; insufficient maternal weigh gain was more characteristic for group 1 compared with other group; excessive maternal weight gain was characteristic for group 3; statistically significant P values are presented in bold letters and marked with an asterisk
| Pre- and peri-natal complications | BMI < 19 kg/m2 | BMI range | BMI > 25 kg/m2 | Significance |
|---|---|---|---|---|
| Antenatal foetal death | 3,7 (1) | – | – | |
| Preterm birth | – | – | 3,9 (4) | |
| Preeclampsia and gestational arterial hypertension | – | 4,6 (10) | 16,7 (17) | |
| Gestational diabetes | – | 5,1 (11) | 10,8 (11) | |
Foetal growth restriction FGR | 11,1 (3) | 1,9 (4) | – | |
| No complications observed | 85,2 (23) | 88,4 (191) | 68,6 (70) | |
| Insufficient weight gain | 33,3 (9) | 29,2 (63) | 13,7 (14) | |
| Normal weight gain | 59,3 (16) | 44,9 (97) | 31,4 (32) | |
| Excessive weight gain | 7,4 (2) | 25,9 (56) | 54,9 (56) |
Fig. 3Pregnancy-associated health risks to mother and offspring identified in groups of comparison; PPPM approach based on pre-pregnancy phenotyping of the mother, health risk assessment and individualised protective and mitigation measures proposed for primary and secondary care; Abbreviations: < –increasing prevalence across the groups 1–3; > –decreasing prevalence across the groups 1–3; FS, Flammer syndrome; CTD, connective tissues dysfunction; PE, preeclampsia; GAH, gestational arterial hypertension; GD, gestational diabetes; ET-1, enddothelin-1